Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PTPRA | P18433 | 1/20 | 0.38 |
| ▸ | PTPRB | P23467 | 1/20 | 0.38 |
| ▸ | PTPRE | P23469 | 1/20 | 0.38 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.35 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MYC | P01106 | 2/20 | 0.35 |
| ▸ | TPMT | P51580 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6887707 | 0.81 | CA12 (0.48) | CA12CA1CA9GAAPTPN1 | |
| SCHEMBL31653832 | 0.80 | KEAP1 (0.43) | CA12CA1CA9GAATP53 | |
| SCHEMBL317703 | 0.80 | KEAP1 (0.43) | CA12CA1CA9GAATP53 | |
| SCHEMBL1834304 | 0.79 | PKM (0.36) | GAAPTPRCPTPN2PTPN1PTPRA | |
| SCHEMBL1464604 | 0.79 | CA12 (0.41) | CA12CA1CA9GAATP53 | |
| SCHEMBL610788 | 0.79 | CA12 (0.41) | CA12CA1CA9GAAPTPN2 | |
| SCHEMBL10627311 | 0.78 | MCL1 (0.42) | CA12CA1CA9GAAPTPN2 | |
| SCHEMBL9596295 | 0.76 | CA12 (0.39) | CA12CA1CA9GAATP53 | |
| SCHEMBL4256629 | 0.76 | GAA (0.41) | CA12CA1CA9GAATP53 | |
| SCHEMBL9262225 | 0.75 | GAA (0.55) | CA12CA1CA9GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724457-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Rayzebio, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-2024254339-A9 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20250257148-A1 | ATP-Dependent Agonists of Immune Cells Function as Anticancer Agents | CROSSLINK THERAPEUTICS INC (US) | 2025-08-14 | — | — | US | disclosed |
| EP-4594337-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING EPHRIN TYPE-A RECEPTOR 2 AND USES THEREOF | Rayzebio, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025054553-A1 | ATP-DEPENDENT AGONISTS OF IMMUNE CELLS FUNCTION AS ANTICANCER AGENTS | CROSSLINK THERAPEUTICS INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2024254339-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024073622-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING EPHRIN TYPE-A RECEPTOR 2 AND USES THEREOF | RAYZEBIO, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-11911488-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | THE JOHNS HOPKINS UNIVERSTY (US) | 2024-02-27 | — | — | US | disclosed |
| US-20200360542-A1 | SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY | THE JOHNS HOPKINS UNIVERSTY | 2020-11-19 | — | — | US | disclosed |
| US-10736974-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-08-11 | — | — | US | disclosed |
| US-20170333576-A1 | NEW SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-11-23 | — | — | US | disclosed |
| US-8093405-B2 | Formation of 18F and 19F fluoroarenes bearing reactive functionalities | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2012-01-10 | — | — | US | disclosed |
| EP-2310362-A1 | FORMATION OF 18F AND 19F FLUOROARENES BEARING REACTIVE FUNCTIONALITIES | University Of Newcastle-Upon Tyne (GB) | 2011-04-20 | — | — | EP | disclosed |
| WO-2009138763-A1 | FORMATION OF 18F AND 19F FLUOROARENES BEARING REACTIVE FUNCTIONALITIES | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2009-11-19 | — | — | WO | disclosed |
| US-20090286992-A1 | FORMATION OF 18F AND 19F FLUOROARENES BEARING REACTIVE FUNCTIONALITIES | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2009-11-19 | — | — | US | disclosed |
| EP-0920623-A4 | BORON NEUTRON CAPTURE THERAPY USING PRE-TARGETING METHODS | IMMUNOMEDICS INC (US) | 2000-03-29 | — | — | EP | disclosed |
| EP-0920623-A1 | BORON NEUTRON CAPTURE THERAPY USING PRE-TARGETING METHODS | Immunomedics, Inc. (US) | 1999-06-09 | — | — | EP | disclosed |
| US-5846741-A | Boron neutron capture therapy using pre-targeting methods | IMMUNOMEDICS, INC. (US) | 1998-12-08 | — | — | US | disclosed |
| WO-1998004917-A1 | BORON NEUTRON CAPTURE THERAPY USING PRE-TARGETING METHODS | IMMUNOMEDICS INC. (US) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200360542-A1 | SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY | FOLH1, PSMA3, PSMA7 | CA12 145/4885CA1 336/4885CA9 288/4885 |
| US-20090286992-A1 | FORMATION OF 18F AND 19F FLUOROARENES BEARING REACTIVE FUNCTIONALITIES | RARB, RARG, RARA | CA12 316/4885CA1 638/4885CA9 1392/4885 |
| US-11911488-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | FOLH1, PSMA3, PSMA7 | CA12 145/4885CA1 336/4885CA9 288/4885 |
| US-20170333576-A1 | NEW SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY | FOLH1, PSMA3, PSMA7 | CA12 257/4885CA1 490/4885CA9 492/4885 |
| US-10736974-B2 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | FOLH1, PSMA3, PSMA7 | CA12 145/4885CA1 336/4885CA9 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.